News Releases

CAPE CANAVERAL, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1

Vaxxinity to present new preclinical data on anti-tau Alzheimer’s vaccine candidate VXX-301 at AD/PD International Conference CAPE CANAVERAL, Fla., March 02, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic

Appointment of new directors bring diversity, balance and relevant industry expertise to Vaxxinity Establishment of Frontier Exploration Laboratories (“VaxxLabs”) in Cape Canaveral, Fla., as corporate headquarters CAPE CANAVERAL, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc.

DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the